Morningstar yesterday placed a 17.3c fair value estimate for Bio-Gene.
Anything under 50c will be seen as a bargain with the right partnerships taking Flavocide and Qcide forward.
Patents which they submitted earlier this year came directly from positive efficacy testing of Flavocide, the 2022 patents are general. We hold the keys to the castle and the IP needed to disrupt the insecticide market.
